Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
PHAT Stock Chart & Stats
$12.63
-$0.22(-3.06%)
At close: 4:00 PM EST
$12.63
-$0.22(-3.06%)
Day’s Range― - ―
52-Week Range$2.21 - $18.31
Previous CloseN/A
Volume285.74K
Average Volume (3M)1.07M
Market Cap
$995.23M
Enterprise Value$867.97M
Total Cash (Recent Filing)$129.97M
Total Debt (Recent Filing)$2.71M
Price to Earnings (P/E)―
Beta2.10
Next Earnings
May 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding78,798,710
10 Day Avg. Volume974,159
30 Day Avg. Volume1,073,032
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue4.96
Enterprise Value/Gross Profit5.69
Enterprise Value/Ebitda-17.68
Forecast
1Y Price Target
$23.86Price Target Upside88.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.28
Revenue Forecast (FY)$332.01M
Bulls Say, Bears Say
Bulls Say
Analyst OutlookRevenue guidance that exceeded consensus and analysts' nearer-term upward revenue revisions, including identification of the stock as a top idea, indicate stronger-than-expected sales momentum and increased investor confidence.
Capital StructureAn equity offering together with a restructured term loan that reduced principal and lowered interest improves financial flexibility and supports the path to operating profitability.
Commercial AdoptionMeaningful increases in VOQUEZNA prescriptions and a large pool of GERD patients not adequately helped by proton pump inhibitors suggest expanding market penetration that could drive sustained sales growth.
Bears Say
Revenue Forecast RiskA slight analyst reduction to a later revenue projection highlights residual doubts about the sustainability of sales growth and the potential for future guidance revisions.
Sales Channel RiskUncertainty about whether broader engagement with primary care physicians will be required creates execution risk that could complicate the sales strategy and raise customer acquisition costs.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $995.23M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is May 12, 2026 which is in 29 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Feb 26, 2026. The company reported -$0.29 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.122.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -0.27.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 78,798,710 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$0.29 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went up 10.065%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.86 (88.92% Upside)
$23.86 (88.92% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 216.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
207.29%
12-Months-Change
Fundamentals
Return on Equity
55.14%
Trailing 12-Months
Asset Growth
-31.35%
Trailing 12-Months
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful operational and financial progress: very strong revenue growth (217% YoY), disciplined expense reductions, improved cash profile via a $130M equity raise and favorable term loan modifications, near-full sales force, and clear guidance to reach operating profitability in Q3 2026 and cash flow positivity in 2027. Key challenges cited include persistently high gross-to-net discounts (55%–59%), remaining absolute expense levels, seasonality and short-term prescription volatility, limited broad Medicare coverage, covenant timing considerations, and competitive risk. On balance, the positive execution items (revenue growth, cost control, capital structure improvements, and commercial traction) outweigh the challenges described.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$23.86
▲(88.92% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.99% Insiders
10.20% Mutual Funds
47.25% Other Institutional Investors
25.39% Public Companies and Individual Investors